Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation.
Homma
Masato
M
Department of Pharmaceutical Sciences, Institute of Clinical Medicine, University of Tsukuba, Ibaraki 305-8575, Japan.
Itagaki
Fumio
F
Yuzawa
Kenji
K
Fukao
Katashi
K
Kohda
Yukinao
Y
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001189:Aryl Hydrocarbon Hydroxylases; D001562:Benzimidazoles / Q000494:pharmacology*; D065731:Cytochrome P-450 CYP2C19; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005091:Exons; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood*; D064747:Lansoprazole; D008875:Middle Aged; D006899:Mixed Function Oxygenases / Q000235:genetics*; D009154:Mutation; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000494:pharmacology*; D054328:Proton Pump Inhibitors; D064750:Rabeprazole; D016559:Tacrolimus / Q000097:blood*
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D007166:Immunosuppressive Agents; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D064750:Rabeprazole; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D009853:Omeprazole; D016559:Tacrolimus